Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY900003 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| LY900003 | DRUG | - |
Inclusion Criteria: 1. Stage IIIB or IV non-small lung cancer 2. Able to visit the doctor's office 3. At least 18 years of age 4. Adequate kidney, adrenal, and liver function Exclusion Criteria: 1. Prior chemotherapy or biologic therapy for NSCLC 2. Central nervous system tumors 3. Pregnant or br...
LY900003 was studied for the treatment of advanced non-small cell lung cancer, specifically in patients with previously untreated disease. It was evaluated in combination with gemcitabine and cisplatin chemotherapy. LY900003 is an investigational small molecule and is not an approved therapy for any indication.
LY900003 was developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company sponsored the Phase 3 clinical trial of the drug in non-small cell lung cancer.
LY900003 reached Phase 3 clinical development. Its single registered trial, NCT00034268, was a Phase 3 study that has since been completed. The drug remains investigational and is not approved for commercial use.
LY900003 was studied in one registered clinical trial, NCT00034268, titled a Phase 3 trial of LY900003 plus gemcitabine and cisplatin versus gemcitabine and cisplatin in patients with advanced, previously untreated non-small cell lung cancer. That trial is completed, and no active trials are listed.
LY900003 is not approved. It is an investigational small molecule that was studied in a completed Phase 3 trial for advanced non-small cell lung cancer. No regulatory approval has been granted for this drug.